Royalty Pharma
RPRX
68.45
+0.73
+1.08%
Royalty Pharma
US · RPRX
#759 by market cap
Listed 2020
68.45
+0.73
+1.08%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Form 144 | Royalty Pharma(RPRX.US) Officer Proposes to Sell 17.62 Million in Common StocksMarket Newswire · 2026/11/17
-
Rating change
UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66Market Newswire · 2026/8/11
-
Rating change
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $68Market Newswire · 2026/9/8
-
Rating change
J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62Market Newswire · 2026/8/11
-
Form 144 | Royalty Pharma(RPRX.US) Officer Proposes to Sell 10.18 Million in Common StocksMarket Newswire · 2026/11/18
-
Rating change
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $67Market Newswire · 2026/10/7
-
Rating change
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $63Market Newswire · 2026/10/9
-
Rating change
J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $74Market Newswire · 2026/11/5
-
Rating change
UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66Market Newswire · 2026/9/8
-
Rating change
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $75Market Newswire · 2026/11/5
-
Rating change
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65Market Newswire · 2026/8/6
-
Rating change
Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/10/12
-
Rating change
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $63Market Newswire · 2026/9/24
-
Royalty Pharma(RPRX.US) Officer Sells US$6.81 Million in Common StockMarket Newswire · 2026/11/19
-
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $80Market Newswire · 2026/11/18
-
Royalty Pharma(RPRX.US) Officer Sells US$17.69 Million in Common StockMarket Newswire · 2026/11/19
-
Rating change
Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66Market Newswire · 2026/8/7
-
Rating change
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/8/7
-
Rating change
Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $70Market Newswire · 2026/8/6
-
Rating change
Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $78Market Newswire · 2026/11/5
-
Rating change
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65Market Newswire · 2026/7/13
-
Rating change
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $64Market Newswire · 2026/5/7
-
Rating change
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy RatingMarket Newswire · 2026/7/10
-
Rating change
Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66Market Newswire · 2026/7/16
-
Rating change
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62Market Newswire · 2026/5/7
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:28 · For reference only, not investment advice and not tailored to your situation.
Royalty Pharma discussion 0 comments